Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2/3, Double-blind, Placebo Controlled Adaptive Study Evaluating the Efficacy and Safety of Momelotinib in Participants With VEXAS Syndrome

NCT07569081 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07569081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07569081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2/3, Double-blind, Placebo Controlled Adaptive Study Evaluating the Efficacy and Safety of Momelotinib in Participants With VEXAS Syndrome
Lead sponsor
GlaxoSmithKline
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
August 5, 2026
Completion date
June 4, 2031
Enrollment
136 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

vexas syndrome